Advertisement

Topics

Aclaris Therapeutics, Inc. Company Profile

06:46 EDT 15th October 2018 | BioPortfolio

Aclaris Therapeutics, Inc., started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. Visit www.aclaristx.com for more information.


News Articles [811 Associated News Articles listed on BioPortfolio]

Aclaris' JAK inhibitor gets FDA fast-track status

Aclaris Therapeutics' topical Janus kinase 1/3 inhibitor ATI-502, being developed to treat patients with alopecia areata, inc -More- 

Aclaris, Cipher to market raised seborrheic keratoses therapy in Canada

Cipher Pharmaceuticals acquired the Canadian rights to commercialize Aclaris Therapeutics' A-101 40% topical solution, which  -More- 

Aclaris launches raised seborrheic keratoses therapy

Aclaris Therapeutics launched FDA-approved Eskata, or hydrogen peroxide, as a topical therapy for raised seborrheic keratoses -More- 

Aclaris Therapeutics to Present at the 2018 American Hair Research Summit

WAYNE, Pa., May 11, 2018 (GLOBE NEWSWIRE) -- Paul Changelian, Ph.D., Vice President, Biology, Aclaris Therapeutics, Inc. (NASDAQ:ACRS), will speak at the 2018 American Hair Research Summit on “Pr...

Aclaris Therapeutics Announces Availability of ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w)

MALVERN, Pa., May 07, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that ESKATA™ is now available for purchase ...

Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in the Journal Cancer Research

WAYNE, Pa., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovat...

Aclaris Therapeutics Announces Appointment of Bryan Reasons as a Director and Chairman of the Audit Committee

WAYNE, Pa., April 24, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing ...

Aclaris Therapeutics to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meeting

WAYNE, Pa., May 15, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innova...

PubMed Articles [448 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [157 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1260 Associated Companies listed on BioPortfolio]

Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc., started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel de...

Aclaris Therapeutics Inc.

Aclaris Therapeutics, Inc., started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel de...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Aclaris Therapeutics, Inc." on BioPortfolio

We have published hundreds of Aclaris Therapeutics, Inc. news stories on BioPortfolio along with dozens of Aclaris Therapeutics, Inc. Clinical Trials and PubMed Articles about Aclaris Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aclaris Therapeutics, Inc. Companies in our database. You can also find out about relevant Aclaris Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record